Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines
Additional serotypes in PCV24 and PCV31, especially those included in PCV31, account for substantial health-economic burden in the United States.
Authors
- Joseph A. Lewnard (ORCID: https://orcid.org/0000-0002-8505-8839)
- Laura King (ORCID: https://orcid.org/0000-0002-7785-4712)
Institutions
- Berkeley Public Health Division (US)
- University of California, Berkeley (US)
Publication Details
- Journal
- Vaccine
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1016/j.vaccine.2024.126310
- Citations
- 10
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 3.87